Table 2 Frequencies of immune-related adverse events (irAEs)
| Â | All cases | Anti-PD-1 antibody | Anti-PD-L1 antibody | Anti-CTLA-4 antibody | Combination of anti-PD-1 and CTLA-4 antibodies | |||||
|---|---|---|---|---|---|---|---|---|---|---|
N (%) | 533 cases | Â | 452 cases | Â | 44 cases | Â | 19 cases | Â | 18 cases | Â |
|  | All grade | Grade ≥ 3 | All grade | Grade ≥ 3 | All grade | Grade ≥ 3 | All grade | Grade ≥ 3 | All grade | Grade ≥ 3 |
All events | 144 (27.0) | 57 (10.7) | 114 (25.2) | 42 (9.3) | 7 (15.9) | 3 (6.8) | 9 (47.4) | 3 (15.8) | 14 (77.8) | 9 (50.0) |
 Liver injury | 35 (6.6) | 19 (3.6) | 24 (5.3) | 12 (2.7) | 2 (4.5) | 0 | 1 (5.03 | 0 | 8 (44.4) | 7 (38.9) |
 Interstitial pneumonia | 32 (6.0) | 14 (2.6) | 31 (6.9) | 13 (2.9) | 1 (2.3) | 1 (2.3) | 0 | 0 | 0 | 0 |
 Hypothyroidism | 33 (6.2) | 2 (0.4) | 25 (5.5) | 1 (0.2) | 2 (4.5) | 0 | 3 (15.8) | 0 | 3 (16.7) | 1 (5.6) |
 Rash | 21 (3.9) | 2 (0.4) | 16 (3.5) | 2 (0.4) | 0 | 0 | 1 (5.3) | 0 | 4 (22.2) | 0 |
 Adrenal insufficiency | 14 (2.6) | 6 (1.1) | 10 (2.2) | 4 (0.9) | 0 | 0 | 2 (10.5) | 1 (5.3) | 2 (11.1) | 1 (5.6) |
 Colitis and diarrhea | 11 (2.1) | 3 (0.6) | 9 (2.0) | 3 (0.6) | 0 | 0 | 1 (5.3) | 0 | 1 (5.6) | 1 (5.6) |
 Autoimmune diabetes | 2 (0.4) | 2 (0.4) | 2 (0.4) | 2 (0.4) | 0 | 0 | 0 | 0 | 0 | 0 |
 Others | 20 (3.8) | 14 (2.6) | 11 (2.4) | 9 (2.0) | 3 (6.8) | 2 (4.5) | 3 (15.8) | 2 (10.5) | 3 (16.7) | 2 (11.1) |